old news from a no name equity research firm. Market clearly reflects that as no reaction was generated as a result of the coverage. Talk to me when goldman/piper / or another big name firm starts to support your thesis.
Not some stupid, small group necessarily, they're pretty sharp but not a biotech expert. Which is weird to get involved at all. Funny enough know someone in the Albany area who uses them. It's interesting that they come out with a sell PT of $6.00. I agree they're not Goldman or Piper, but Goldman doesn't have an analyst out with a PT on Vanda anyway. So why does this group come out with such an aggressive sell and PT. They're not underwriting anything for Vanda nor would they be allowed to provide a sell recommendation if they knew a secondary offering were coming. They might have clients invested in Vanda or who knows. The next 30 days will be interesting. Something has to give.. either it's way up or way down.